What Is CJC-1295 No DAC Peptide? (Research Mechanism)
Research conducted at the University of North Carolina found that modifying GHRH (growth hormone-releasing hormone) analogs with a Drug Affinity Complex extends half-life from minutes to days. But that modification fundamentally alters the compound's behavior in biological systems. CJC-1295 no DAC peptide is the unmodified version: a 29-amino-acid analog of GHRH that binds to pituitary receptors, stimulates endogenous growth hormone secretion, and clears from circulation within 30 minutes. The 'no DAC' designation isn't marketing language. It specifies that this compound lacks the albumin-binding modification that creates sustained release.
Our team has worked with research institutions evaluating peptide protocols for years. The distinction between DAC and no DAC variants matters far more than most literature acknowledges. It's not about 'better' or 'worse,' it's about matching half-life to experimental design.
What is CJC-1295 no DAC peptide used for in research?
CJC-1295 no DAC peptide is a synthetic GHRH analog used in research to stimulate pulsatile growth hormone release without the extended half-life modification created by Drug Affinity Complex binding. It reaches peak plasma concentration within 10–15 minutes, stimulates GH secretion through anterior pituitary GHRH receptor activation, and clears within 30 minutes. Allowing researchers to study acute GH dynamics without multi-day systemic exposure. This pharmacokinetic profile makes it the standard choice for protocols requiring precise temporal control over growth hormone signaling.
Most literature conflates CJC-1295 with its DAC-modified counterpart, treating them as interchangeable variants. They're not. The no DAC version operates on an entirely different timeline. Short pulsatile stimulation rather than sustained baseline elevation. Which is why serious research distinguishing between physiological GH patterns and pharmacological intervention requires the unmodified form. This article covers the biochemical mechanism, the structural difference DAC modification creates, how pharmacokinetics drive protocol design, and what preparation and handling errors compromise research validity.
The Biochemical Mechanism: GHRH Receptor Activation Without Albumin Binding
CJC-1295 no DAC peptide functions as a GHRH receptor agonist. It binds to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs and initiates the intracellular cascade that results in growth hormone synthesis and secretion. The compound is a 29-amino-acid analog of endogenous GHRH, with four substitutions that increase stability against enzymatic degradation (specifically dipeptidyl peptidase-4, the enzyme that rapidly cleaves natural GHRH). Without DAC modification, plasma half-life extends from the 7-minute half-life of endogenous GHRH to approximately 30 minutes. Still short enough to mimic physiological pulsatility.
Here's what differentiates this from DAC-modified CJC-1295: the Drug Affinity Complex is a reactive chemical group that covalently binds to serum albumin after injection, creating a reservoir that slowly releases active peptide over days. That albumin attachment extends half-life to 6–8 days, creating sustained rather than pulsatile GH elevation. Research protocols studying circadian GH patterns, acute metabolic response, or receptor desensitization kinetics require the no DAC version. DAC-modified CJC-1295 introduces a fundamentally different pharmacodynamic profile that doesn't reflect endogenous physiology.
Our experience working with labs on peptide storage and reconstitution shows that most protocol failures stem from assuming 'CJC-1295' is a single compound. It's not. Specifying 'no DAC' ensures the research team receives the short-acting analog rather than the albumin-binding variant, which matters when experimental windows are measured in hours rather than weeks.
Pharmacokinetics and Half-Life: Why 30 Minutes Changes Everything
The 30-minute half-life of CJC-1295 no DAC peptide is the entire reason it exists as a distinct research tool. Growth hormone secretion in mammals follows an ultradian rhythm. Pulsatile release every 3–5 hours rather than continuous baseline elevation. DAC-modified CJC-1295 disrupts that rhythm by maintaining elevated plasma levels for days; the no DAC version preserves it by clearing between pulses.
Peak plasma concentration occurs 10–15 minutes post-administration, GH secretion peaks 20–30 minutes later, and plasma levels return to baseline within 90 minutes. This pharmacokinetic profile allows researchers to administer doses at specific circadian timepoints (e.g., before anticipated endogenous GH pulses during deep sleep) without creating sustained supraphysiological GH exposure. Studies evaluating receptor sensitivity, downstream IGF-1 response kinetics, or metabolic effects tied to GH pulsatility all require this temporal precision.
A 2014 study published in the Journal of Clinical Endocrinology & Metabolism compared pulsatile vs continuous GH administration in aging adults and found that pulsatile delivery preserved insulin sensitivity while continuous administration did not. The pattern of exposure mattered as much as total dose. CJC-1295 no DAC peptide is the tool that allows researchers to replicate pulsatile patterns in controlled settings. The compound doesn't produce sustained GH elevation the way exogenous recombinant GH or DAC-modified analogs do. It amplifies endogenous pulses and clears, which is mechanistically different.
Structural Chemistry: What 'No DAC' Actually Means at the Molecular Level
The Drug Affinity Complex modification involves attaching a maleimide-derivatized lysine residue to position 15 of the GHRH analog sequence, which reacts with cysteine-34 on human serum albumin after subcutaneous injection. This covalent bond creates a high-molecular-weight complex (the peptide bound to albumin) that circulates for days rather than minutes. Removing that modification. Producing CJC-1295 no DAC peptide. Leaves the 29-amino-acid sequence intact but without the albumin-binding capacity.
The four amino acid substitutions that differentiate CJC-1295 from endogenous GHRH are Ala2, D-Ala8, Gln15, and Leu27. These substitutions increase resistance to dipeptidyl peptidase-4 degradation without altering receptor binding affinity. The result is a peptide that binds GHRH receptors with similar affinity to natural GHRH but resists enzymatic breakdown for 30 minutes instead of 7 minutes. Long enough to produce meaningful GH secretion but short enough to avoid sustained receptor occupancy.
Why does this matter for research protocols? Because albumin binding fundamentally changes biodistribution and clearance. DAC-modified CJC-1295 accumulates in circulation, crosses fewer tissue barriers (albumin-bound compounds have restricted extravasation), and produces steady-state GH elevation. CJC-1295 no DAC peptide distributes more freely, clears renally, and produces discrete GH peaks. Research evaluating tissue-specific GH signaling, metabolic cycling, or receptor downregulation kinetics requires the unmodified compound. Real Peptides synthesizes both variants under controlled conditions, but researchers must specify which version matches their protocol design.
What Is CJC-1295 No DAC Peptide?: Research vs DAC-Modified Comparison
Half-Life
~30 minutes
6–8 days
No DAC suits pulsatile GH studies; DAC suits sustained-release models
No DAC preserves physiological GH rhythm. Critical for receptor sensitivity research
Peak GH Response
20–30 min post-injection
Sustained baseline elevation
No DAC mimics endogenous ultradian pulses; DAC creates pharmacological steady-state
Pulsatility vs continuity is the mechanistic difference. Not potency
Albumin Binding
None
Covalent bond via maleimide-lysine
No DAC clears renally; DAC persists in circulation bound to albumin
Biodistribution differs. DAC-bound peptides have restricted tissue access
Dosing Frequency
Multiple administrations per protocol window
Single administration lasts days
No DAC requires timing precision; DAC simplifies dosing but alters pharmacodynamics
Protocol complexity increases with no DAC but experimental control improves
Receptor Occupancy Pattern
Brief, pulsatile
Sustained, continuous
No DAC allows receptor recovery between pulses; DAC risks desensitization
Chronic receptor stimulation with DAC may confound long-term metabolic studies
Key Takeaways
CJC-1295 no DAC peptide is a 29-amino-acid GHRH analog with a 30-minute half-life, designed to stimulate pulsatile growth hormone release without albumin binding.
The 'no DAC' designation specifies the absence of Drug Affinity Complex modification. The chemical group that creates covalent albumin binding and extends half-life to 6–8 days.
Peak plasma GH concentration occurs 20–30 minutes after administration, and levels return to baseline within 90 minutes. Matching endogenous ultradian GH rhythm.
Research protocols studying receptor sensitivity, metabolic cycling, or acute GH dynamics require the no DAC version. DAC-modified CJC-1295 produces sustained GH elevation that doesn't reflect physiological patterns.
Proper reconstitution with bacteriostatic water and refrigerated storage at 2–8°C are non-negotiable. Temperature excursions or improper mixing denature the peptide structure and eliminate activity.
The four amino acid substitutions (Ala2, D-Ala8, Gln15, Leu27) increase resistance to dipeptidyl peptidase-4 degradation without altering GHRH receptor binding affinity.
What If: CJC-1295 No DAC Peptide Scenarios
What If the Reconstituted Peptide Looks Cloudy or Has Visible Particles?
Discard it immediately and do not use it in any experimental protocol. Cloudiness or particulate matter indicates protein aggregation or contamination. Both compromise biological activity and introduce confounding variables. Properly reconstituted CJC-1295 no DAC peptide should be clear and colorless. Aggregation occurs when reconstitution is performed incorrectly (shaking instead of gentle swirling, injecting bacteriostatic water too forcefully, using non-sterile water) or when the lyophilized powder was exposed to temperature excursions before reconstitution. Cloudy peptide solutions contain denatured or partially-degraded protein that won't bind GHRH receptors reliably.
What If the Peptide Was Left at Room Temperature for Several Hours?
If lyophilized powder was left at room temperature (20–25°C) for under 48 hours, refrigerate it immediately and use it. Short-term ambient exposure doesn't significantly degrade lyophilized peptides. If reconstituted solution was left at room temperature for more than 2 hours, discard it. Once mixed with bacteriostatic water, CJC-1295 no DAC peptide must be stored at 2–8°C and used within 28 days. Room-temperature exposure accelerates enzymatic degradation and bacterial growth (even with bacteriostatic water, which slows but doesn't eliminate microbial proliferation). Peptides stored improperly lose potency unpredictably. There's no way to verify activity without mass spectrometry, so the safest protocol is strict cold-chain adherence.
What If You Need to Transport Reconstituted CJC-1295 No DAC Peptide?
Use a medical-grade insulated cooler with refrigerant packs that maintain 2–8°C for the duration of transport. Standard ice packs allow temperature fluctuations that cause freeze-thaw cycles (peptides should never freeze once reconstituted. Ice crystal formation disrupts tertiary structure). Purpose-built peptide transport kits use phase-change materials that hold a stable 4–6°C range for 36–48 hours without electrical input. If transport exceeds 48 hours, coordinate with a cold-chain logistics provider. Peptides are not like small-molecule drugs. Temperature sensitivity is extreme, and single excursions above 8°C can denature the protein irreversibly.
The Uncompromising Truth About CJC-1295 No DAC Peptide
Here's the honest answer: most research-grade peptide failures aren't caused by impure synthesis. They're caused by improper handling after the peptide arrives at the lab. CJC-1295 no DAC peptide is a temperature-sensitive protein that degrades rapidly when mishandled. Leaving it at room temperature, reconstituting it with tap water instead of bacteriostatic water, shaking the vial instead of swirling gently, or storing it in a standard refrigerator that cycles between 4°C and 10°C will compromise activity. And there's no visual cue to tell you it's degraded. A clear solution looks identical whether it's 100% active or 30% active. This is why chain-of-custody and storage verification matter as much as synthesis purity.
The second uncomfortable truth: 'CJC-1295' sold without specifying DAC vs no DAC is almost always the DAC-modified version, because it's more forgiving to ship and store. If a supplier doesn't explicitly state 'no DAC' or 'modified GRF 1-29' (another name for the unmodified analog), assume it contains the albumin-binding modification. Research protocols requiring pulsatile GH stimulation will produce confounded results if the wrong variant is used, and most published studies don't clarify which version was administered. Creating reproducibility problems across the literature.
Reconstitution, Storage, and Handling: Where Most Protocols Fail
Lyophilized CJC-1295 no DAC peptide must be stored at −20°C before reconstitution. Once you're ready to use it, allow the vial to reach room temperature before adding bacteriostatic water. Injecting cold water into a cold vial causes condensation and uneven mixing. Add water slowly down the side of the vial (never directly onto the powder), and swirl gently until fully dissolved. Never shake. Shaking introduces air bubbles and mechanical stress that denature peptides.
Reconstituted solution must be refrigerated at 2–8°C and used within 28 days. Bacteriostatic water (0.9% benzyl alcohol) inhibits bacterial growth but doesn't sterilize. Contamination is still possible if aseptic technique isn't followed. Draw doses using a fresh sterile syringe each time; never reinsert a used needle into the vial. Each needle puncture introduces potential contamination, and repeated punctures degrade the rubber stopper.
The most common mistake we see: storing reconstituted peptides in a household refrigerator that fluctuates between 3°C and 9°C during defrost cycles. Those temperature swings accelerate degradation. Lab-grade refrigerators with continuous monitoring are the standard for peptide storage. If that's not available, use a calibrated thermometer inside the storage unit and verify temperature stability over 48 hours before trusting it with reconstituted peptides. Real Peptides provides handling protocols with every order, but adherence to those protocols is what separates reliable research from confounded data.
CJC-1295 no DAC peptide isn't a forgiving compound. Handle it with the same rigor you'd apply to any recombinant protein. Temperature excursions, improper reconstitution, and contaminated draws are the variables that introduce noise into experimental results, and they're entirely preventable with proper lab practice. The peptide does exactly what it's designed to do. Stimulate GHRH receptors, trigger GH secretion, and clear within 30 minutes. If you give it the conditions it requires to remain structurally intact. That responsibility sits with the research team, not the synthesis lab.
Frequently Asked Questions
CJC-1295 with DAC contains a Drug Affinity Complex modification that covalently binds to serum albumin, extending half-life to 6–8 days and creating sustained GH elevation. CJC-1295 no DAC peptide lacks this modification, resulting in a 30-minute half-life and pulsatile GH secretion that mirrors endogenous physiology. The pharmacokinetic and pharmacodynamic profiles are fundamentally different — DAC modification is not a potency enhancement, it’s a sustained-release mechanism that alters the compound’s behavior in biological systems.
Reconstituted CJC-1295 no DAC peptide remains stable for up to 28 days when stored at 2–8°C in bacteriostatic water. Beyond 28 days, degradation accelerates and potency declines unpredictably. Lyophilized powder stored at −20°C can remain stable for 12–24 months, but once reconstituted, the 28-day window is a hard limit. Temperature excursions above 8°C or freeze-thaw cycles after reconstitution cause irreversible protein denaturation.
Yes, CJC-1295 no DAC peptide is frequently studied in combination with GHRP-2, GHRP-6, ipamorelin, or hexarelin — compounds that stimulate GH release through the ghrelin receptor rather than the GHRH receptor. The two pathways are synergistic: GHRH receptor activation increases the amplitude of GH pulses, while ghrelin receptor activation increases pulse frequency. Research protocols often combine a GHRH analog with a GHRP to study combined receptor stimulation, but dosing, timing, and experimental endpoints must be carefully controlled to isolate which mechanism produces observed effects.
Reconstitution volume depends on the total peptide mass in the vial and the desired concentration for dosing precision. A common standard is 2 mL of bacteriostatic water per 2 mg of lyophilized peptide, yielding a 1 mg/mL concentration. Researchers requiring smaller doses may use 1 mL per 2 mg (2 mg/mL concentration) to reduce injection volume. The peptide will dissolve fully in any volume between 1–3 mL — the choice is driven by dosing accuracy and the volume capacity of the syringes used for administration.
Lyophilized CJC-1295 no DAC peptide should be stored at −20°C before reconstitution for maximum long-term stability, but it tolerates short-term storage at 2–8°C (refrigerated) or even room temperature (20–25°C) for up to 48 hours without significant degradation. Once reconstituted, refrigeration at 2–8°C is mandatory — reconstituted peptide left at room temperature degrades within hours. The lyophilized form is far more stable than the reconstituted solution, which is why cold-chain protocols focus on post-reconstitution handling.
There are no reliable visual indicators of peptide degradation — a clear, colorless solution can be fully degraded and still appear normal. The only definitive test is mass spectrometry or HPLC analysis. Cloudiness, particulate matter, or discoloration indicate contamination or aggregation and require immediate disposal. Subtle potency loss from improper storage (e.g., temperature excursions, prolonged reconstitution beyond 28 days) is undetectable without analytical testing, which is why strict adherence to storage protocols is the only safeguard.
CJC-1295 no DAC peptide is typically administered subcutaneously — absorption is rapid, bioavailability is high, and the injection is less invasive than intramuscular administration. Subcutaneous injection into adipose tissue (abdomen, thigh, or upper arm) allows the peptide to enter systemic circulation within 10–15 minutes. Intramuscular injection is not contraindicated but offers no pharmacokinetic advantage and increases tissue trauma. Research protocols almost universally specify subcutaneous administration unless comparing delivery routes as an experimental variable.
Yes, CJC-1295 no DAC peptide and modified GRF 1-29 are the same compound — both refer to the 29-amino-acid GHRH analog with four amino acid substitutions (Ala2, D-Ala8, Gln15, Leu27) that increase stability without albumin binding. The naming inconsistency exists because ‘CJC-1295’ originally referred only to the DAC-modified version, but suppliers and researchers began using ‘CJC-1295 no DAC’ to specify the unmodified analog. ‘Modified GRF 1-29’ is the more precise chemical designation and avoids confusion, but both terms describe the same peptide sequence.
Injecting degraded CJC-1295 no DAC peptide produces no adverse effects beyond wasted material — the degraded peptide fragments are biologically inert and are cleared renally without toxicity. The issue is experimental validity: a protocol using degraded peptide will produce null results or inconsistent data, confounding the research question. There’s no safety risk from injecting inactive peptide, but there’s significant risk to research integrity if storage failures aren’t detected before administration.
The 30-minute half-life requires researchers to administer CJC-1295 no DAC peptide at specific timepoints aligned with experimental endpoints — unlike DAC-modified CJC-1295, which maintains activity for days regardless of administration timing. Protocols studying acute GH response administer the peptide 20–30 minutes before anticipated measurement windows. Protocols studying pulsatile GH dynamics may dose multiple times per day (e.g., before sleep to coincide with endogenous nocturnal GH pulses). The short half-life is an asset for temporal precision but requires tighter protocol adherence than sustained-release analogs.